Short Interest in OptimizeRx Co. (NASDAQ:OPRX) Rises By 145.8%

OptimizeRx Co. (NASDAQ:OPRX) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 511,000 shares, an increase of 145.8% from the June 15th total of 207,900 shares. Based on an average trading volume of 118,400 shares, the short-interest ratio is presently 4.3 days. Currently, 5.3% of the company’s shares are short sold.

Separately, Zacks Investment Research downgraded Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $19.00.

In other news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of OptimizeRx stock in a transaction on Monday, May 13th. The stock was sold at an average price of $13.64, for a total transaction of $1,120,198.64. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in shares of OptimizeRx during the second quarter worth about $51,000. BlackRock Inc. acquired a new position in shares of OptimizeRx during the fourth quarter worth about $55,000. Westwood Management Corp IL acquired a new position in shares of OptimizeRx during the first quarter worth about $127,000. Bank of America Corp DE grew its position in shares of OptimizeRx by 15.8% during the fourth quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock worth $168,000 after buying an additional 2,084 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of OptimizeRx by 71.5% during the fourth quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock worth $192,000 after buying an additional 7,283 shares in the last quarter. 48.47% of the stock is owned by institutional investors.

NASDAQ OPRX traded up $0.48 during trading on Friday, hitting $15.59. The stock had a trading volume of 49,125 shares, compared to its average volume of 80,285. The company has a market capitalization of $188.56 million, a P/E ratio of 311.80, a PEG ratio of 1.72 and a beta of 0.51. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.02 and a quick ratio of 4.02. The business’s 50 day moving average is $15.06. OptimizeRx has a twelve month low of $8.92 and a twelve month high of $18.39.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: Strangles

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.